Jesús Cámara Gómez - Academia.edu (original) (raw)
Uploads
Papers by Jesús Cámara Gómez
Journal of Allergy and Clinical Immunology, 2003
RATIONALE: Because of the central role of interleukin-5 (IL-5) in eosinophil homeostasis, a pilot... more RATIONALE: Because of the central role of interleukin-5 (IL-5) in eosinophil homeostasis, a pilot trial of the anti-lL-5 humanized monoclonal antibody SCH55700 (Schering-Plough) in subjects with eosinophilic gastroenteritis (EG) and food allergy was conducted. METHODS: A single dose of SCH55700 was given at 1 mg/kg IV and peripheral blood and gastrointestinal eosinophils were serially examined. RESULTS: Four subjects with baseline peripheral blood absolute eosinophil counts (AEC) between 1200 and 2500/fl received SCH55700. All subjects had a rapid decline in AEC, with mean drops of 70% (range: 49-85%) and 83% (range: 73-94%) at 24 and 48 hours, respectively. This decrease was sustained through the 4-week time point. Upper endoscopy was performed before study drug and at the 4-week time point and tissue eosinophils were quantitated using H&E staining. Three of the 4 subjects showed a 50-70% drop in gastrointestinal eosinophils, whereas one subject demonstrated a 43% increase. Overall symptom scores were not improved. Seven to 8 weeks after the single dose of SCH55700, 2 of the 4 subjects had a rebound in their disease, with both AEC values and symptom scores substantially greater than their pre-drug values (maximum AEC 3,600 and 15,000). After an additional 2-4 weeks their AEC and symptoms returned to baseline. CONCLUSIONS: These data demonstrate that both the peripheral blood and tissue eosinophilia found in EG is responsive to IL-5 blockade. In light of the lack of symptom response, these findings suggest that additional mediator blockade may be required to completely suppress the clinical manifestations of this disorder.
Clinical & Translational Oncology, 2005
Introduction von Willebrand factor (vWf) is thought to mediate binding of tumour cells to platele... more Introduction von Willebrand factor (vWf) is thought to mediate binding of tumour cells to platelets and to favour their systemic spreading capacity. Platelets involved in tumour angiogenesis are capable of releasing vascular endothelial growth factor (VEGF). Hence, levels of vWf and VEGF may correlate with cancer stage. The objectives are determine the impact of surgery and chemotherapy on vWf and VEGF in colorectal cancer (CRC) patients. Material and methods Twenty healthy volunteers (group 1), 14 patients with locally advanced CRC (group 2) and 12 patients with metastatic CRC (group 3) were enrolled. Blood samples were taken at recruitment in group 1, and before and after surgery and chemotherapy in groups 2 and 3, respectively. Blood levels of vWf, VEGF, platelet count, C-reactive protein (CRP), ceruloplasmin and carcinoembrionary antigen (CEA) were measured. Results At baseline, group 3 showed higher concentrations of vWf than the other groups (p<0.05). In group 2, vWf became elevated 40% post-surgery (p=0.016), independently of changes in CRP or ceruloplasmin. In group 3, chemotherapy caused a 42% reduction in VEGF (p=0.015). Conclusions There was a strong correlation between higher vWf levels and more advanced CRC stage at diagnosis. These levels were elevated post-surgery in patients with locally advanced CRC. Chemotherapy significantly decreased VEGF in metastatic CRC patients before CEA showed any significant change.
Clinical & Translational Oncology, 2005
von Willebrand factor (vWf) is thought to mediate binding of tumour cells to platelets and to fav... more von Willebrand factor (vWf) is thought to mediate binding of tumour cells to platelets and to favour their systemic spreading capacity. Platelets involved in tumour angiogenesis are capable of releasing vascular endothelial growth factor (VEGF). Hence, levels of vWf and VEGF may correlate with cancer stage. The objectives are determine the impact of surgery and chemotherapy on vWf and VEGF in colorectal cancer (CRC) patients. Twenty healthy volunteers (group 1), 14 patients with locally advanced CRC (group 2) and 12 patients with metastatic CRC (group 3) were enrolled. Blood samples were taken at recruitment in group 1, and before and after surgery and chemotherapy in groups 2 and 3, respectively. Blood levels of vWf, VEGF, platelet count, C-reactive protein (CRP), ceruloplasmin and carcinoembrionary antigen (CEA) were measured. At baseline, group 3 showed higher concentrations of vWf than the other groups (p&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;0.05). In group 2, vWf became elevated 40% post-surgery (p=0.016), independently of changes in CRP or ceruloplasmin. In group 3, chemotherapy caused a 42% reduction in VEGF (p=0.015). There was a strong correlation between higher vWf levels and more advanced CRC stage at diagnosis. These levels were elevated post-surgery in patients with locally advanced CRC. Chemotherapy significantly decreased VEGF in metastatic CRC patients before CEA showed any significant change.
... El Laboratori té cambres Hasselblad per a fotografìa aèria i pot subministrar, juntarnent amb... more ... El Laboratori té cambres Hasselblad per a fotografìa aèria i pot subministrar, juntarnent amb les imat-ges digitals, fotografíes preses amb cambres Wild RC-10. La qualitat de les imatges obtíngu-des depèn, en gran mesura, de les condi-cions en qué es van adquirir. ...
Regional Anesthesia and Pain Medicine, 2001
We assessed the efficacy and safety of dipyrone in comparison with tramadol in the relief of earl... more We assessed the efficacy and safety of dipyrone in comparison with tramadol in the relief of early postoperative pain following abdominal hysterectomy. A total of 151 women between 18 and 60 years of age undergoing abdominal hysterectomy during general anesthesia participated in a randomized, double-blind, controlled, multicenter study. Seventy-three patients received dipyrone and 78 received tramadol. Patients received an intravenous loading dose of the study drug immediately after operation followed by intravenous (IV) maintenance infusion and IV on-demand boluses up to a maximum number of predetermined doses/day of 8 g dipyrone and 500 mg tramadol. The duration of the study was 24 hours. The mean (SD) number of boluses in the dipyrone group was 3.8 (2.4) and 3.5 (2.5) in the tramadol group (95% confidence interval, -0.455 to 1.175), and the percentage of patients requiring rescue IV morphine (dipyrone 26.9%, tramadol 26.8%) was not statistically significant. Other analgesic efficacy parameters, such as pain intensity differences, sum of pain intensity differences, pain relief assessed by the patient, or patients who required the maximum number of demand doses, were not different between treatment groups. A significantly higher percentage of adverse gastrointestinal effects was found in patients given tramadol (42.1%) than in patients given dipyrone (20.2%) (P <.05). Also, a significantly higher number of tramadol-treated patients required ondansetron to control nausea and vomiting at 1 hour (19% v 7%), 2 hours (26% v 11%), and 24 hours (46% v 29%) (P <.05) after surgery. Patients and the investigators reported similar tolerability for both study arms. Dipyrone and tramadol showed similar efficacy for early pain relief after abdominal hysterectomy. Nausea and vomiting, possibly caused by the tramadol, occurred more frequently in those patients. In this group, the need of the antiemetic drug ondansetron was also higher.
Journal of Allergy and Clinical Immunology, 2003
RATIONALE: Because of the central role of interleukin-5 (IL-5) in eosinophil homeostasis, a pilot... more RATIONALE: Because of the central role of interleukin-5 (IL-5) in eosinophil homeostasis, a pilot trial of the anti-lL-5 humanized monoclonal antibody SCH55700 (Schering-Plough) in subjects with eosinophilic gastroenteritis (EG) and food allergy was conducted. METHODS: A single dose of SCH55700 was given at 1 mg/kg IV and peripheral blood and gastrointestinal eosinophils were serially examined. RESULTS: Four subjects with baseline peripheral blood absolute eosinophil counts (AEC) between 1200 and 2500/fl received SCH55700. All subjects had a rapid decline in AEC, with mean drops of 70% (range: 49-85%) and 83% (range: 73-94%) at 24 and 48 hours, respectively. This decrease was sustained through the 4-week time point. Upper endoscopy was performed before study drug and at the 4-week time point and tissue eosinophils were quantitated using H&E staining. Three of the 4 subjects showed a 50-70% drop in gastrointestinal eosinophils, whereas one subject demonstrated a 43% increase. Overall symptom scores were not improved. Seven to 8 weeks after the single dose of SCH55700, 2 of the 4 subjects had a rebound in their disease, with both AEC values and symptom scores substantially greater than their pre-drug values (maximum AEC 3,600 and 15,000). After an additional 2-4 weeks their AEC and symptoms returned to baseline. CONCLUSIONS: These data demonstrate that both the peripheral blood and tissue eosinophilia found in EG is responsive to IL-5 blockade. In light of the lack of symptom response, these findings suggest that additional mediator blockade may be required to completely suppress the clinical manifestations of this disorder.
Clinical & Translational Oncology, 2005
Introduction von Willebrand factor (vWf) is thought to mediate binding of tumour cells to platele... more Introduction von Willebrand factor (vWf) is thought to mediate binding of tumour cells to platelets and to favour their systemic spreading capacity. Platelets involved in tumour angiogenesis are capable of releasing vascular endothelial growth factor (VEGF). Hence, levels of vWf and VEGF may correlate with cancer stage. The objectives are determine the impact of surgery and chemotherapy on vWf and VEGF in colorectal cancer (CRC) patients. Material and methods Twenty healthy volunteers (group 1), 14 patients with locally advanced CRC (group 2) and 12 patients with metastatic CRC (group 3) were enrolled. Blood samples were taken at recruitment in group 1, and before and after surgery and chemotherapy in groups 2 and 3, respectively. Blood levels of vWf, VEGF, platelet count, C-reactive protein (CRP), ceruloplasmin and carcinoembrionary antigen (CEA) were measured. Results At baseline, group 3 showed higher concentrations of vWf than the other groups (p<0.05). In group 2, vWf became elevated 40% post-surgery (p=0.016), independently of changes in CRP or ceruloplasmin. In group 3, chemotherapy caused a 42% reduction in VEGF (p=0.015). Conclusions There was a strong correlation between higher vWf levels and more advanced CRC stage at diagnosis. These levels were elevated post-surgery in patients with locally advanced CRC. Chemotherapy significantly decreased VEGF in metastatic CRC patients before CEA showed any significant change.
Clinical & Translational Oncology, 2005
von Willebrand factor (vWf) is thought to mediate binding of tumour cells to platelets and to fav... more von Willebrand factor (vWf) is thought to mediate binding of tumour cells to platelets and to favour their systemic spreading capacity. Platelets involved in tumour angiogenesis are capable of releasing vascular endothelial growth factor (VEGF). Hence, levels of vWf and VEGF may correlate with cancer stage. The objectives are determine the impact of surgery and chemotherapy on vWf and VEGF in colorectal cancer (CRC) patients. Twenty healthy volunteers (group 1), 14 patients with locally advanced CRC (group 2) and 12 patients with metastatic CRC (group 3) were enrolled. Blood samples were taken at recruitment in group 1, and before and after surgery and chemotherapy in groups 2 and 3, respectively. Blood levels of vWf, VEGF, platelet count, C-reactive protein (CRP), ceruloplasmin and carcinoembrionary antigen (CEA) were measured. At baseline, group 3 showed higher concentrations of vWf than the other groups (p&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;0.05). In group 2, vWf became elevated 40% post-surgery (p=0.016), independently of changes in CRP or ceruloplasmin. In group 3, chemotherapy caused a 42% reduction in VEGF (p=0.015). There was a strong correlation between higher vWf levels and more advanced CRC stage at diagnosis. These levels were elevated post-surgery in patients with locally advanced CRC. Chemotherapy significantly decreased VEGF in metastatic CRC patients before CEA showed any significant change.
... El Laboratori té cambres Hasselblad per a fotografìa aèria i pot subministrar, juntarnent amb... more ... El Laboratori té cambres Hasselblad per a fotografìa aèria i pot subministrar, juntarnent amb les imat-ges digitals, fotografíes preses amb cambres Wild RC-10. La qualitat de les imatges obtíngu-des depèn, en gran mesura, de les condi-cions en qué es van adquirir. ...
Regional Anesthesia and Pain Medicine, 2001
We assessed the efficacy and safety of dipyrone in comparison with tramadol in the relief of earl... more We assessed the efficacy and safety of dipyrone in comparison with tramadol in the relief of early postoperative pain following abdominal hysterectomy. A total of 151 women between 18 and 60 years of age undergoing abdominal hysterectomy during general anesthesia participated in a randomized, double-blind, controlled, multicenter study. Seventy-three patients received dipyrone and 78 received tramadol. Patients received an intravenous loading dose of the study drug immediately after operation followed by intravenous (IV) maintenance infusion and IV on-demand boluses up to a maximum number of predetermined doses/day of 8 g dipyrone and 500 mg tramadol. The duration of the study was 24 hours. The mean (SD) number of boluses in the dipyrone group was 3.8 (2.4) and 3.5 (2.5) in the tramadol group (95% confidence interval, -0.455 to 1.175), and the percentage of patients requiring rescue IV morphine (dipyrone 26.9%, tramadol 26.8%) was not statistically significant. Other analgesic efficacy parameters, such as pain intensity differences, sum of pain intensity differences, pain relief assessed by the patient, or patients who required the maximum number of demand doses, were not different between treatment groups. A significantly higher percentage of adverse gastrointestinal effects was found in patients given tramadol (42.1%) than in patients given dipyrone (20.2%) (P <.05). Also, a significantly higher number of tramadol-treated patients required ondansetron to control nausea and vomiting at 1 hour (19% v 7%), 2 hours (26% v 11%), and 24 hours (46% v 29%) (P <.05) after surgery. Patients and the investigators reported similar tolerability for both study arms. Dipyrone and tramadol showed similar efficacy for early pain relief after abdominal hysterectomy. Nausea and vomiting, possibly caused by the tramadol, occurred more frequently in those patients. In this group, the need of the antiemetic drug ondansetron was also higher.